Author
Home > Health > What is the Difference Between Levodopa and Carbidopa?

Guilherme Mazui

•4 minutes to read

What is the Difference Between Levodopa and Carbidopa?

🆚 Go to Comparative Table 🆚

Levodopa and carbidopa are both used in the treatment of Parkinson's disease, but they have different functions and are often combined to reduce side effects. The main differences between them are:

  • Function: Levodopa is a central nervous system agent that works by being converted to dopamine in the brain, while carbidopa is a decarboxylase inhibitor that prevents levodopa from being broken down before it reaches the brain.
  • Dosage: Carbidopa allows for a lower dose of levodopa, which causes less nausea and vomiting.
  • Formulations: Levodopa and carbidopa can be combined in different ratios, such as levodopa/benserazide and levodopa/carbidopa 100/10 mg. One example of a branded medicine containing carbidopa and levodopa is Rytary, which is available in an extended-release capsule formulation.
  • Side Effects: The therapeutic efficacy and side effects of levodopa with carbidopa or benserazide are generally similar, depending on the daily dose of levodopa and the different ratios of decarboxylase inhibitors to levodopa.

In summary, while both levodopa and carbidopa are used to treat Parkinson's disease, they have different functions and are often combined to optimize treatment and reduce side effects. The choice of formulation depends on factors such as the patient's specific needs, the severity of their symptoms, and the desired release profile of the medication.

On this page
  • What is the Difference Between Levodopa and Carbidopa?
  • Comparative Table: Levodopa vs Carbidopa

    • Comparative Table: Levodopa vs Carbidopa

    Levodopa and Carbidopa are two medications used in the treatment of Parkinson's disease. They are often combined in different formulations to manage the disease effectively. Here is a table highlighting the differences between the two:

    Feature Levodopa Carbidopa
    Function Levodopa is a natural chemical that passes into the brain and is converted into dopamine, a neurotransmitter involved in controlling movement. It is the main component in the treatment of Parkinson's disease. Carbidopa is a decarboxylase inhibitor that reduces the side effects of levodopa, such as nausea, by partially suppressing its peripheral metabolism. It is often combined with levodopa to maximize its therapeutic potential.
    Formulations Levodopa can be found in both immediate-release (IR) and extended-release (ER) formulations. IR formulations provide a quick release of the medication, while ER formulations provide a more steady and continuous release. Carbidopa is typically combined with levodopa in various formulations, such as IR and ER tablets and enteral suspension.
    Dosage The typical starting dosage of carbidopa-levodopa ER tablets is one 50 mg/200 mg tablet twice a day, taken at least 6 hours apart. Dosages can be increased every 3 days or more until the desired dosage is reached. Maintenance doses can be given as often as every 4 hours or as infrequently as every 8 hours. Dosages of up to 1,600 mg of levodopa per day are enough for most people, but some may need higher dosages. Carbidopa-levodopa IR and ER tablets are not absorbed the same way by the body, so the dosage may need to be adjusted when switching between the two formulations.
    Side Effects The main side effect of levodopa is nausea, which can be minimized by combining it with carbidopa. Carbidopa reduces the side effects of levodopa, such as nausea and lightheadedness, by partially suppressing its peripheral metabolism.

    In summary, levodopa is the main component in the treatment of Parkinson's disease, while carbidopa is combined with levodopa to reduce its side effects and maximize its therapeutic potential. They are available in different formulations, including immediate-release and extended-release tablets, and their dosages may need to be adjusted depending on the individual's needs and response to the medication.

    Read more:

    Guilherme Mazui

    Guilherme Mazui is graduated in journalism from the Federal University of Minas Gerais (UFMG) and a master's degree in Communication from the University of SĂŁo Paulo (USP). In addition, he has experience in advertising writing and has worked as a content editor in several companies.